{"type":"trials","record":{"id":41506,"source_id":"clinicaltrials-gov","external_id":"NCT06161584","title":"A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration","brief_summary":"A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration","overall_status":"Active Not Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Apellis Pharmaceuticals, Inc.","enrollment":300,"countries":["United States"],"start_date":"2023-09-28","completion_date":"2027-06-01","last_update_date":"2026-06-01","source_url":"https://clinicaltrials.gov/study/NCT06161584","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"60 Years","comparator":null,"organization":"Apellis Pharmaceuticals, Inc.","interventions":["Pegcetacoplan"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Incidence of ocular AEs in treated eyes overall and according to physician-directed treatment interval based on US pres…","Incidence of other events of interest — Up to 36 months","Assess real-world treatment patterns and use of pegcetacoplan considering the proportion of participants with bilateral…","If only one eye is treated, the criteria for determination of the eye to be treated — Up to 36 months","The treatment interval (mean days between injections) over time — Up to 36 months","The frequency of imaging on treated eyes (color fundus photography, spectral domain optical coherence tomography [SD-OC…","The treatment adherence to planned dosing frequency: the number of injections administered divided by the number of inj…","The duration of persistence on treatment: continuous medication usage until a gap of ≥3 months — Up to 36 months","The treatment discontinuation and/or switching to other agents approved for treatment of GA — Up to 36 months","The management of new-onset exudative age-related macular degeneration (eAMD) events in eyes treated with pegcetacoplan…","The proportion of treated eyes that develop eAMD that receive anti-vascular endothelial growth factor (VEGF) injections…","The number of anti-VEGF injections per month from diagnosis of eAMD — Up to 36 months","The proportion of anti-VEGF injections given on same day in the same eye as pegcetacoplan — Up to 36 months"],"design_description":null,"source_has_results":false},"controlled_terms":["Geographic Atrophy","Pegcetacoplan"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06161584","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-09-28 to 2027-06-01","comparator":null,"confidence":"structured-source","population":"ALL · 60 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.824Z","intervention":["Pegcetacoplan"],"participants":300,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Incidence of ocular AEs in treated eyes overall and according to physician-directed treatment interval based on US pres…","Incidence of other events of interest — Up to 36 months","Assess real-world treatment patterns and use of pegcetacoplan considering the proportion of participants with bilateral…","If only one eye is treated, the criteria for determination of the eye to be treated — Up to 36 months","The treatment interval (mean days between injections) over time — Up to 36 months","The frequency of imaging on treated eyes (color fundus photography, spectral domain optical coherence tomography [SD-OC…","The treatment adherence to planned dosing frequency: the number of injections administered divided by the number of inj…","The duration of persistence on treatment: continuous medication usage until a gap of ≥3 months — Up to 36 months","The treatment discontinuation and/or switching to other agents approved for treatment of GA — Up to 36 months","The management of new-onset exudative age-related macular degeneration (eAMD) events in eyes treated with pegcetacoplan…","The proportion of treated eyes that develop eAMD that receive anti-vascular endothelial growth factor (VEGF) injections…","The number of anti-VEGF injections per month from diagnosis of eAMD — Up to 36 months","The proportion of anti-VEGF injections given on same day in the same eye as pegcetacoplan — Up to 36 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41506","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}